Phil Vanek

CTO & Partner, Gamma Biosciences

Role: Associate

Sites: CDL-Oxford, CDL-Toronto, CDL-Vancouver, CDL-Wisconsin

Stream: Advanced Therapies

An entrepreneurial and strategic international business leader, Phil joined Gamma Biosciences in 2020 from Cytiva’s Cell and Gene Therapy business. At Gamma, Phil is responsible for technical diligence of potential investments, as well as guiding operational, R&D and strategic initiatives carried out at portfolio companies. Phil received his Ph.D. in Biochemistry and Molecular Biology at Georgetown University Medical Center, with research focused in molecular oncology. Phil was an instructor at Johns Hopkins University’s Biotechnology Marketing in the Masters of Biotechnology / MBA program, and has held strategy and innovation leadership positions in a number of life sciences companies including Life Technologies, Becton Dickinson, and Lonza. Phil is a Board Member of CCRM in Toronto Canada and a Board Member of the Foundation for Cell and Gene Medicine.